Gain Therapeutics, Inc. – NASDAQ:GANX
Gain Therapeutics stock price today
$1.7
-0.06
-3.41%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Gain Therapeutics stock price monthly change
+27.54%
month
Gain Therapeutics stock price quarterly change
+27.54%
quarter
Gain Therapeutics stock price yearly change
-36.46%
year
Gain Therapeutics key metrics
Market Cap | 41.64M |
Enterprise value | 46.83M |
P/E | -2.98 |
EV/Sales | 167.13 |
EV/EBITDA | -1.83 |
Price/Sales | 190.83 |
Price/Book | 2.83 |
PEG ratio | 0.37 |
EPS | -1.5 |
Revenue | N/A |
EBITDA | -21.35M |
Income | -21.14M |
Revenue Q/Q | -100% |
Revenue Y/Y | -77.68% |
Profit margin | -9260.29% |
Oper. margin | -9364.89% |
Gross margin | 0% |
EBIT margin | -9364.89% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGain Therapeutics stock price history
Gain Therapeutics stock forecast
Gain Therapeutics financial statements
| Jun 2023 | 0 | -7.68M | |
|---|---|---|---|
| Sep 2023 | 0 | -4.71M | |
| Dec 2023 | 64.8K | -4.72M | -7290.08% |
| Mar 2024 | 0 | -4.01M |
| Dec 2023 | 64.8K | -4.72M | -7290.08% |
|---|---|---|---|
| Mar 2024 | 0 | -4.01M | |
| Oct 2025 | 50K | -5.12M | -10248% |
| Dec 2025 | 50K | -5.12M | -10248% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 18260874 | 7.16M | 39.25% |
|---|---|---|---|
| Sep 2023 | 14097448 | 6.76M | 48% |
| Dec 2023 | 18609331 | 6.03M | 32.41% |
| Mar 2024 | 14577184 | 5.93M | 40.72% |
| Jun 2023 | -5.02M | 3.04M | 2.19M |
|---|---|---|---|
| Sep 2023 | -3.96M | 1.92M | 134.47K |
| Dec 2023 | -5.66M | 3.14M | 9.56M |
| Mar 2024 | -3.58M | 3.01M | -145.80K |
Gain Therapeutics alternative data
| Aug 2023 | 28 |
|---|---|
| Sep 2023 | 28 |
| Oct 2023 | 28 |
| Nov 2023 | 28 |
| Dec 2023 | 28 |
| Jan 2024 | 28 |
| Feb 2024 | 28 |
| Mar 2024 | 28 |
| Apr 2024 | 28 |
| May 2024 | 29 |
| Jun 2024 | 29 |
| Jul 2024 | 29 |
Gain Therapeutics other data
2.02%
-8.14%
of GANX is owned by hedge funds
11
-10
239.94K
-966.81K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 2026 |
| Mar 2024 | 30000 | 0 |
| Jul 2024 | 17000 | 0 |
| Insider | Compensation |
|---|---|
Dr. Manolo Bellotto Ph.D. (1971) Pres & GM | $251,990 |
Mr. Eric I. Richman M.B.A. (1961) Chief Executive Officer & Director | $213,290 |
Mr. Salvatore Calabrese (1970) Chief Financial Officer | $117,110 |
-
What's the price of Gain Therapeutics stock today?
One share of Gain Therapeutics stock can currently be purchased for approximately $1.7.
-
When is Gain Therapeutics's next earnings date?
Unfortunately, Gain Therapeutics's (GANX) next earnings date is currently unknown.
-
Does Gain Therapeutics pay dividends?
No, Gain Therapeutics does not pay dividends.
-
How much money does Gain Therapeutics make?
Gain Therapeutics has a market capitalization of 41.64M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 60.62% to 55.18K US dollars.
-
What is Gain Therapeutics's stock symbol?
Gain Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "GANX".
-
What is Gain Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Gain Therapeutics?
Shares of Gain Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Gain Therapeutics's key executives?
Gain Therapeutics's management team includes the following people:
- Dr. Manolo Bellotto Ph.D. Pres & GM(age: 54, pay: $251,990)
- Mr. Eric I. Richman M.B.A. Chief Executive Officer & Director(age: 64, pay: $213,290)
- Mr. Salvatore Calabrese Chief Financial Officer(age: 55, pay: $117,110)
-
How many employees does Gain Therapeutics have?
As Jul 2024, Gain Therapeutics employs 29 workers, which is 4% more then previous quarter.
-
When Gain Therapeutics went public?
Gain Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 19 Mar 2021.
-
What is Gain Therapeutics's official website?
The official website for Gain Therapeutics is gaintherapeutics.com.
-
Where are Gain Therapeutics's headquarters?
Gain Therapeutics is headquartered at 4800 Montgomery Lane, Bethesda, MD.
-
How can i contact Gain Therapeutics?
Gain Therapeutics's mailing address is 4800 Montgomery Lane, Bethesda, MD and company can be reached via phone at +30 15001556.
Gain Therapeutics company profile:
Gain Therapeutics, Inc.
gaintherapeutics.comExchange:
NASDAQ
Full time employees:
29
Industry:
Biotechnology
Sector:
Healthcare
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
4800 Montgomery Lane
Bethesda, MD 20814
Bethesda, MD 20814
CIK: 0001819411
ISIN: US36269B1052
CUSIP: 36269B105
